

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 61675

**Title:** Programmed cell death protein-1 inhibitor combined with antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

**Reviewer's code:** 05488289

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-12-15

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-12-16 12:35

**Reviewer performed review:** 2020-12-16 13:07

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

1. This paper describes a 61 year old male patient with diarrhea and edema of lower extremities for 15 days. There was a large mass in the pelvic cavity. The pathological results showed that it was non Hodgkin's diffuse large B-cell lymphoma (DLBCL). After 3 cycles of R-CHOP Regimen, the patient was diagnosed as relapsed and refractory DLBCL. The combination of PD-1 inhibitor and car-t cells showed significant therapeutic effect. The DNA copy numbers of car-cd19t cells and car-cd22t cells were stable. At present, the patient has been disease-free survival for more than 10 months. It is suggested that the expression of PD-1 may affect the therapeutic effect of car-t cells, and the combination of car-t cells and PD-1 inhibitors provides a new idea for the treatment of relapsed and refractory NHL. 2. The case has a certain clinical significance, and the treatment ideas show good curative effect, which is worthy of reference. 3. The writing idea of this article is clear and the case features are displayed in detail. However, the discussion is not deep enough. 4. It is suggested to accept and publish after modification.